COMMUNIQUÉS West-GlobeNewswire

-
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
02/07/2025 -
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
02/07/2025 -
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02/07/2025 -
Ipsen inaugure son nouveau siège social mondial à Paris, en présence du ministre délégué chargé de la Santé et de l'Accès aux Soins Yannick Neuder
02/07/2025 -
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
02/07/2025 -
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
02/07/2025 -
Informations relatives au nombre total de droits de vote et d’actions composant le capital
02/07/2025 -
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
02/07/2025 -
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
02/07/2025 -
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
02/07/2025 -
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
02/07/2025 -
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.
02/07/2025 -
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
02/07/2025 -
Middlesex Recovery Unveils Brand Refresh to Reflect Unified Identity with BayMark Health Services
02/07/2025 -
AppleGate Recovery Unveils Brand Refresh Aligned with BayMark Health Services Continuum of Care
02/07/2025 -
Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral
02/07/2025 -
Extendicare Acquires Closing the Gap Healthcare Group
02/07/2025 -
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
02/07/2025 -
Highest THCa Flower July 2025: New Hemp Hop Strains Hit the Market
02/07/2025
Pages